Further, the expression of Glut5 and IL-6 was found to be positively corelated in clinical samples of OSCC, prostate cancer, colorectal cancer and glioma, suggesting that the IL-6-medited Glut5 expression probably widely exist in multiple human cancers. Here, SLC2A5 is linked to Familial prostate cancer.